NZ334580A - Sibutramine analogues to prevent the development of diabetes - Google Patents
Sibutramine analogues to prevent the development of diabetesInfo
- Publication number
- NZ334580A NZ334580A NZ334580A NZ33458097A NZ334580A NZ 334580 A NZ334580 A NZ 334580A NZ 334580 A NZ334580 A NZ 334580A NZ 33458097 A NZ33458097 A NZ 33458097A NZ 334580 A NZ334580 A NZ 334580A
- Authority
- NZ
- New Zealand
- Prior art keywords
- insulin
- cyclobutyl
- chlorophenyl
- dimethyl
- diabetes
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical class C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 3
- 229940125396 insulin Drugs 0.000 abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 abstract 1
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 abstract 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 abstract 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001761 chlorpropamide Drugs 0.000 abstract 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 abstract 1
- 229950009226 ciglitazone Drugs 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- 229960000346 gliclazide Drugs 0.000 abstract 1
- 229960004346 glimepiride Drugs 0.000 abstract 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 abstract 1
- 229960001381 glipizide Drugs 0.000 abstract 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229940125395 oral insulin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000000580 secretagogue effect Effects 0.000 abstract 1
- 230000001235 sensitizing effect Effects 0.000 abstract 1
- 229960002277 tolazamide Drugs 0.000 abstract 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 abstract 1
- 229960005371 tolbutamide Drugs 0.000 abstract 1
- 229960001641 troglitazone Drugs 0.000 abstract 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 abstract 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619757.9A GB9619757D0 (en) | 1996-09-21 | 1996-09-21 | Chemical process |
| PCT/EP1997/005039 WO1998011884A1 (en) | 1996-09-21 | 1997-09-15 | Use of sibutramine analogues to prevent the development of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ334580A true NZ334580A (en) | 2000-09-29 |
Family
ID=10800326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ334580A NZ334580A (en) | 1996-09-21 | 1997-09-15 | Sibutramine analogues to prevent the development of diabetes |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US6174925B1 (https=) |
| EP (1) | EP0927028A1 (https=) |
| JP (1) | JP2001503737A (https=) |
| KR (1) | KR20000048501A (https=) |
| CN (1) | CN1237905A (https=) |
| AU (1) | AU724488B2 (https=) |
| BG (1) | BG64473B1 (https=) |
| BR (1) | BR9711517A (https=) |
| CA (1) | CA2266401C (https=) |
| CZ (1) | CZ93699A3 (https=) |
| GB (1) | GB9619757D0 (https=) |
| HR (1) | HRP970505A2 (https=) |
| HU (1) | HUP9904026A3 (https=) |
| ID (1) | ID18320A (https=) |
| IL (1) | IL128850A (https=) |
| MY (1) | MY116150A (https=) |
| NO (1) | NO991358D0 (https=) |
| NZ (1) | NZ334580A (https=) |
| PL (1) | PL332305A1 (https=) |
| RU (1) | RU2245709C2 (https=) |
| SK (1) | SK31999A3 (https=) |
| TR (1) | TR199900618T2 (https=) |
| TW (1) | TW580385B (https=) |
| UA (1) | UA64726C2 (https=) |
| WO (1) | WO1998011884A1 (https=) |
| ZA (1) | ZA978450B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
| JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
| AR019727A1 (es) * | 1998-06-30 | 2002-03-13 | Takeda Chemical Industries Ltd | Composicion farmaceutica |
| US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6974838B2 (en) * | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
| US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
| CZ20011629A3 (cs) * | 1998-11-12 | 2001-12-12 | Smithkline Beecham Plc | Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků |
| AR023699A1 (es) * | 1998-11-12 | 2002-09-04 | Smithkline Beecham Corp | Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica |
| US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
| US6696495B2 (en) | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
| US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
| US6552087B1 (en) | 1999-03-19 | 2003-04-22 | Abbott Gmbh & Co. Kg | Therapeutic agent comprising (+)-sibutramine |
| US6680344B1 (en) | 1999-06-01 | 2004-01-20 | The University Of Texas Southwestern Medical Center | Method of treating hair loss using diphenylmethane derivatives |
| WO2000072810A1 (en) | 1999-06-01 | 2000-12-07 | The University Of Texas Southwestern Medical Center | Method of treating hair loss using sulfonyl thyromimetic compounds |
| US6723717B1 (en) | 1999-06-01 | 2004-04-20 | The University Of Texas Southwestern Medical Center | Sulfur-containing thyroxane derivatives and their use as hair growth promotors |
| GB9914744D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
| US6399826B1 (en) | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
| WO2002083631A1 (en) | 2001-04-13 | 2002-10-24 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
| US8911781B2 (en) | 2002-06-17 | 2014-12-16 | Inventia Healthcare Private Limited | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides |
| NZ538966A (en) * | 2002-10-05 | 2006-11-30 | Hanmi Pharm | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate |
| US20050131074A1 (en) * | 2003-08-04 | 2005-06-16 | Beckman Kristen M. | Methods for treating metabolic syndrome |
| PE20050335A1 (es) * | 2003-08-07 | 2005-06-01 | Sb Pharmco Inc | Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion |
| GB0318824D0 (en) * | 2003-08-11 | 2003-09-10 | Glaxo Group Ltd | Novel composition |
| CA2540225C (en) * | 2003-10-31 | 2012-03-06 | Takeda Pharmaceutical Company Limited | Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester |
| KR100627687B1 (ko) * | 2005-04-20 | 2006-09-25 | 주식회사 씨티씨바이오 | 시부트라민 유리염기 함유 조성물 및 이의 제조방법 |
| BRPI0706365A2 (pt) | 2006-01-06 | 2011-03-22 | Sepracor Inc | Cicloalquilaminas como inibidores da recaptação de monoamina |
| CA2663254C (en) | 2006-09-15 | 2016-04-19 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cycloalkylmethylamines |
| KR100812538B1 (ko) * | 2006-10-23 | 2008-03-11 | 한올제약주식회사 | 약물 제어방출형 메트포르민-글리메피리드 복합제제 |
| KR20080046601A (ko) * | 2006-11-22 | 2008-05-27 | 에스케이케미칼주식회사 | 보관안정성이 우수한 시부트라민 함유 포접복합체 |
| DK2118123T3 (en) | 2007-01-31 | 2016-01-25 | Dana Farber Cancer Inst Inc | Stabilized p53 peptides and uses thereof |
| US8592377B2 (en) | 2007-03-28 | 2013-11-26 | President And Fellows Of Harvard College | Stitched polypeptides |
| US9237864B2 (en) | 2009-07-02 | 2016-01-19 | Dexcom, Inc. | Analyte sensors and methods of manufacturing same |
| WO2012003501A2 (en) | 2010-07-02 | 2012-01-05 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
| ES2711526T3 (es) | 2010-08-13 | 2019-05-06 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| US9238625B2 (en) | 2011-12-30 | 2016-01-19 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives |
| BR112014020103A2 (pt) | 2012-02-15 | 2018-10-09 | Aileron Therapeutics, Inc. | macrociclos peptidomiméticos |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52768B1 (en) * | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
| GB8531071D0 (en) * | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| GB8704777D0 (en) * | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
| JP2675573B2 (ja) * | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
| IE61928B1 (en) * | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| WO1995010292A1 (en) | 1993-10-14 | 1995-04-20 | Biomedica California, Inc. | Diabetes treatment and prophylaxis |
| US5459164A (en) * | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
| GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
-
1996
- 1996-09-21 GB GBGB9619757.9A patent/GB9619757D0/en active Pending
-
1997
- 1997-09-15 US US09/254,924 patent/US6174925B1/en not_active Expired - Lifetime
- 1997-09-15 RU RU99108468/14A patent/RU2245709C2/ru not_active IP Right Cessation
- 1997-09-15 CA CA002266401A patent/CA2266401C/en not_active Expired - Fee Related
- 1997-09-15 KR KR1019990702397A patent/KR20000048501A/ko not_active Ceased
- 1997-09-15 EP EP97910288A patent/EP0927028A1/en not_active Ceased
- 1997-09-15 IL IL12885097A patent/IL128850A/xx not_active IP Right Cessation
- 1997-09-15 HU HU9904026A patent/HUP9904026A3/hu unknown
- 1997-09-15 SK SK319-99A patent/SK31999A3/sk unknown
- 1997-09-15 CZ CZ99936A patent/CZ93699A3/cs unknown
- 1997-09-15 BR BR9711517A patent/BR9711517A/pt not_active IP Right Cessation
- 1997-09-15 TR TR1999/00618T patent/TR199900618T2/xx unknown
- 1997-09-15 PL PL97332305A patent/PL332305A1/xx unknown
- 1997-09-15 NZ NZ334580A patent/NZ334580A/xx not_active IP Right Cessation
- 1997-09-15 AU AU47740/97A patent/AU724488B2/en not_active Ceased
- 1997-09-15 JP JP51427198A patent/JP2001503737A/ja not_active Ceased
- 1997-09-15 CN CN97199787A patent/CN1237905A/zh active Pending
- 1997-09-15 UA UA99042263A patent/UA64726C2/uk unknown
- 1997-09-15 WO PCT/EP1997/005039 patent/WO1998011884A1/en not_active Ceased
- 1997-09-18 HR HR9619757.9A patent/HRP970505A2/hr not_active Application Discontinuation
- 1997-09-19 ZA ZA978450A patent/ZA978450B/xx unknown
- 1997-09-20 MY MYPI97004383A patent/MY116150A/en unknown
- 1997-09-22 ID IDP973256A patent/ID18320A/id unknown
- 1997-09-24 TW TW086113897A patent/TW580385B/zh not_active IP Right Cessation
-
1999
- 1999-03-19 NO NO991358A patent/NO991358D0/no not_active Application Discontinuation
- 1999-03-24 BG BG103277A patent/BG64473B1/bg unknown
-
2000
- 2000-10-30 US US09/702,125 patent/US6617360B1/en not_active Expired - Fee Related
-
2003
- 2003-08-15 US US10/641,506 patent/US20040077730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL128850A0 (en) | 2000-01-31 |
| NO991358L (no) | 1999-03-19 |
| HUP9904026A3 (en) | 2000-07-28 |
| CN1237905A (zh) | 1999-12-08 |
| KR20000048501A (ko) | 2000-07-25 |
| JP2001503737A (ja) | 2001-03-21 |
| PL332305A1 (en) | 1999-08-30 |
| GB9619757D0 (en) | 1996-11-06 |
| BR9711517A (pt) | 1999-08-24 |
| MY116150A (en) | 2003-11-28 |
| RU2245709C2 (ru) | 2005-02-10 |
| BG103277A (en) | 2000-01-31 |
| SK31999A3 (en) | 1999-12-10 |
| AU4774097A (en) | 1998-04-14 |
| IL128850A (en) | 2003-07-31 |
| ZA978450B (en) | 1999-03-19 |
| WO1998011884A1 (en) | 1998-03-26 |
| TR199900618T2 (xx) | 1999-06-21 |
| ID18320A (id) | 1998-03-26 |
| CA2266401C (en) | 2007-01-30 |
| HUP9904026A2 (hu) | 2000-05-28 |
| AU724488B2 (en) | 2000-09-21 |
| CZ93699A3 (cs) | 1999-08-11 |
| US6174925B1 (en) | 2001-01-16 |
| UA64726C2 (uk) | 2004-03-15 |
| US6617360B1 (en) | 2003-09-09 |
| NO991358D0 (no) | 1999-03-19 |
| HRP970505A2 (en) | 1998-08-31 |
| TW580385B (en) | 2004-03-21 |
| BG64473B1 (bg) | 2005-04-30 |
| US20040077730A1 (en) | 2004-04-22 |
| CA2266401A1 (en) | 1998-03-26 |
| EP0927028A1 (en) | 1999-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ334580A (en) | Sibutramine analogues to prevent the development of diabetes | |
| RU99108468A (ru) | Применение аналогов сибутрамина для профилактики сахарного диабета | |
| IL112515A (en) | Pharmaceutical composition containing N,N-dimethyl-1-¬1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine for use in the treatment of non-insulin dependent diabetes mellitus | |
| TR199903057T2 (xx) | Diabetin tiazolidinedion ve metformin ile tedavisi. | |
| Luna et al. | Oral agents in the management of type 2 diabetes mellitus | |
| TWI241185B (en) | Antidiabetic formulation | |
| Korytkowski | Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride | |
| KR100643833B1 (ko) | 인슐린 감작제 및 다른 항당뇨병 약제의 개선된 방출을위한 제약 조성물 | |
| WO2002005795B1 (en) | Pharmaceutical combinations for treatment and prevention of diabetes mellitus | |
| AU2006222060B2 (en) | Roflumilast for the treatment of diabetes mellitus | |
| CA2314940A1 (en) | Improved medication delivery pen | |
| WO2007035665A1 (en) | Use of a dpp-iv inhibitor to reduce hypoglycemic events | |
| WO1998056378A1 (en) | Novel niddm regimen | |
| RU2001131722A (ru) | 5-[4-(6-Метокси-1-метил-1Н-бензимидазол-2-илметокси)бензил]-тиазолидин-2,4 -ди он гидрохлорид, обладающий гипогликемической активностью | |
| TR200401145T4 (tr) | Gliburit ve milrinonun sinerjistik etkisi. | |
| CA2296653A1 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide | |
| HU228260B1 (en) | Pharmaceutical compositions to treat impaired glucose tolerance | |
| CA2113856A1 (en) | Antidiabetic Agent | |
| NZ515555A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| ES2166406T3 (es) | Uso de derivados de 1,5-benzodiazepina para el control del vaciado gastrico en pacientes con diabetes mellitus no dependiente de insulina. | |
| CA2575521A1 (en) | Medicinal composition containing diabetes remedy | |
| JP2007504213A5 (https=) | ||
| BR0309375A (pt) | Tratamento de sìndrome metabólica | |
| HU188015B (en) | Process for the preparation of antidiabetes compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |